AbbVie
Tracked across 24 events · 297 articles · First seen Apr 17, 2025 · Last active Aug 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: AbbVie has deployed its wealth planning platform at Belgium, strengthening its position in the European banking market and expanding its reach to Personal Banking clients.
Jun 11, 2026 · 6 articles
Regulatory
The United Arab Emirates — Emirates Drug Establishment (EDE) of the United Arab Emirates has approved the expanded use of RINVOQ (upadacitinib), an oral JAK inhibitor developed by AbbVie, for the treatment of non-segmental vitiligo…
Impact: AbbVie's RINVOQ received its first global approval for vitiligo, expanding its therapeutic indications and potentially boosting revenue, while strengthening its immunology portfolio.
Aug 17, 2026 · 6 articles
Tech
Impact: AbbVie>>> developed Mirvetuximab soravtansine, the new ovarian cancer drug. The approval of Mirvetuximab soravtansine by the United Kingdom — National Health Service>>> is a major commercial success for AbbVie>>>, potentially boosting its revenue and stock value.
Jun 03, 2026 · 9 articles
International
Impact: AbbVie is being investigated by the United States — House Select Committee on the Chinese Communist Party regarding its clinical trials in China, especially in China — Xinjiang and at military hospitals. This investigation highlights ethical and security risks for AbbVie and could lead to negative market sentiment and regulatory challenges.
Apr 20, 2026 · 8 articles
Business
Impact: AbbVie is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Business
Nxera Pharma reported its consolidated results for the second quarter ended 30 June 2026, showing a significant improvement in financial performance. Revenue increased to JPY 18,910 million (US$119.6 million), up from JPY 15,095 million in…
Impact: AbbVie achieved third and fourth research milestones under its collaboration with Nxera, resulting in US$20 million in milestone payments to Nxera. This reflects progress in neurological disease programs.
Aug 07, 2026 · 6 articles
Regulatory
Impact: AbbVie is expected to announce a deal with the Donald Trump administration after the holidays.
Dec 19, 2025 · 7 articles
Tech
Impact: AbbVie Inc. is a funding partner for the project, supporting the research into Alzheimer s disease biomarkers.
Feb 19, 2026 · 6 articles
Tech
Impact: Employer of Marc Weinberg; not involved in the study, but associated through employee.
Jul 06, 2026 · 6 articles
Business
Impact: AbbVie's acquisition of Apogee Therapeutics is part of the M&A activity boosting biotech valuations and investor sentiment.
Jul 06, 2026 · 25 articles
Business
Impact: AbbVie is mentioned as a developer of an approved BTK inhibitor, Imbruvica, which is a competitor to bexobrutideg.
Jun 07, 2026 · 22 articles
Business
Impact: AbbVie is a joint venture partner in Abbvie Therapeutics India Private Limited, mentioned as an associate company.
Jul 07, 2026 · 14 articles
Regulatory
Impact: AbbVie now owns the brand Pred Forte, but is not directly affected by the recall of the generic version.
Jul 07, 2026 · 38 articles
Business
Piramal Enterprises — Piramal Pharma Solutions (PPS), a CDMO and part of Piramal Group, launched a new spray drying suite at its dedicated peptide development and manufacturing facility in Turbhe, India. The suite is a…
Impact: Mentioned as partner in a joint venture with Piramal Pharma; not directly impacted by this expansion.
Aug 04, 2026 · 12 articles
Business
On August 18, 2026, Piramal Group (PPL) completed the acquisition of an additional 40.67% stake in Yapan Bio, a Hyderabad-based CDMO specializing in vaccines and biologics, for a cash consideration of ₹76 crore (approximately $7.95…
Impact: Mentioned as partner in an associate company; not directly impacted by this acquisition.
Jul 20, 2026 · 11 articles
Business
Impact: Mentioned as part of 2026 M&A activity; acquired Apogee for $10.9B.
Jul 06, 2026 · 34 articles
Business
Impact: AbbVie is a competitor that previously acquired KC Pharmaceuticals for up to $1.2B in 2024, highlighting industry interest in psychedelic therapies.
Jul 16, 2026 · 25 articles
Business
Impact: AbbVie is a joint venture partner in Abbvie Therapeutics India Private Limited, mentioned as an associate company.
Jul 29, 2026 · 10 articles
Business
Impact: Ramakrishna Venugopalan previously led combination product drug development at AbbVie; the event does not directly affect AbbVie.
Jul 30, 2026 · 6 articles
100
United Arab Emirates — Emirates Drug Establishment approved expanded use AbbVieUAE approves RINVOQ for vitiligo
80
Nxera Pharma achieved milestones AbbVieNxera Pharma Q2 2026 Results
Coeptis Therapeutics Holdings
none
↔
AbbVie
AbbVie does not have a direct business relationship with Coeptis Therapeutics Ho
Bain Capital
no direct relation
↔
AbbVie
AbbVie acquired Cerevel Therapeutics, a company in which Bain Capital was a majo
Coeptis Therapeutics Holdings
none
↔
AbbVie
Coeptis Therapeutics Holdings does not have a direct business relationship with
Bain Capital
no direct relation
↔
AbbVie
Bain Capital was a major investor in Cerevel Therapeutics, which AbbVie acquired
ERGEN INTELLIGENCE
Track AbbVie live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard